ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,264 GBX | +1.20% |
|
+1.67% | +15.70% |
| 05-08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
| 05-08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
153.2
USD
Average target price
166.5
USD
Spread / Average Target
+8.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.70% | 236B | |
| +32.95% | 700B | |
| -4.97% | 358B | |
| +18.83% | 330B | |
| +3.54% | 287B | |
| +6.68% | 202B | |
| -9.08% | 197B | |
| +6.70% | 161B | |
| -1.81% | 157B | |
| +3.70% | 124B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca Unit To Buy US Biotech LogicBio Therapeutics
